January 27, 2015 8:38 PM ET

Pharmaceuticals

Company Overview of Takeda Pharmaceuticals International GmbH

Company Overview

Takeda Pharmaceuticals International GmbH, a pharmaceutical company, manufactures and markets patented products, branded generics, and over-the-counter products that treat patients in various therapeutic areas worldwide. It offers its products in the areas of cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine (gastrointestinal and genitourinary), and vaccines. The company also provides packaging, development, contract manufacturing, and quality control services. Takeda Pharmaceuticals International GmbH was formerly known as Nycomed International Management GmbH and changed its name to Takeda Pharmaceuticals International GmbH in Dece...

Thurgauerstrasse 130

Glattpark-Opfikon,  8152

Switzerland

Founded in 1874

Phone:

41 44 555 10 00

Fax:

41 44 555 10 01

Key Executives for Takeda Pharmaceuticals International GmbH

Chief Executive Officer
Age: 68
Corporate Officer and President of Europe & Canada Business Unit
Head of Commercial Operations - Emerging Markets
Executive Vice President of Human Resources and IS/IT
Age: 56
Director of External Communications
Compensation as of Fiscal Year 2014.

Takeda Pharmaceuticals International GmbH Key Developments

Valeant Canada Acquires Rights to Edarbi and Edarbyclor for the Canadian Market from Takeda Pharmaceuticals International GmbH

Valeant Canada announced it has acquired the Canadian rights to Edarbi™ (azilsartan medoxomil) and Edarbyclor™ (azilsartan medoxomil and chlorthalidone), two products from Takeda Pharmaceutical International GmbH that have been approved by Health Canada, and are indicated for hypertension. The rights were acquired through a license, distribution and supply agreement between affiliates of Valeant Canada and Takeda Pharmaceutical International. The licensing of these complementary products supports Valeant Canada's desire to meet patient treatment needs and to build on its current product offering to physicians in the cardio-metabolic field, which already includes Lodalis, Tiazac XC and Glumetza.

Takeda Pharmaceuticals International Gmbh Announces Management Changes

Takeda Pharmaceutical Company Limited announced that Marc Princen joined Takeda Pharmaceuticals International GmbH as Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit. In his new role, Princen will lead all business operations in Europe and Canada, and he will report directly to Christophe Weber, the President and Chief Operating Officer of Takeda. Princen brings more than 25 years of experience in the pharmaceutical industry including roles in a diverse array of functions such as commercial, marketing, business development and management across the globe, specifically, the United States, the Middle East and Africa, as well as several countries in Europe. Most recently, Princen served as President of the Mid-Europe Region at Merck based in Switzerland, and before that served as President and General Manager of Diversified Brands. Trevor Smith decided to leave Takeda and transition his professional home base to the United Kingdom after commuting to Zurich for several years. Smith will step down effective November 1, 2014 and will facilitate the transition of leadership until his departure from Takeda Pharmaceuticals International GmbH on March 31, 2015.

Apricus Biosciences Launches Erectile Dysfunction Treatment in UK

Apricus Biosciences has launched an on-demand treatment for erectile dysfunction called Vitaros. The company announced that Vitaros will be marketed in the United Kingdom by Takeda Pharmaceuticals International GmbH. The erectile dysfunction market in the United Kingdom was approximately $200 million in 2013 based on prescription sales, making it one of the larger erectile dysfunction markets in Europe. The European PDE-5 inhibitor market is approximately $1.5 billion as estimated by IMS Health, and analyst estimates for ex-US Vitaros sales are in the range of $300 million at peak. Apricus announced that it had received multiple commercial product orders of Vitaros from its partners and is currently manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe. The company announced that commercialization of Vitaros has been fully licensed to these partners, with Apricus positioned to earn tiered double-digit royalties and more than $200 million in potential milestone payments.

Similar Private Companies By Industry

Company Name Region
Devirex AG Europe
AVVA Pharmaceuticals AG Europe
Acino Pharma AG Europe
IVAX International GmbH Europe
Neurochem (International) Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Takeda Pharmaceuticals International GmbH, please visit www.tpi.takeda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.